Clofilium

Drug Profile

Clofilium

Alternative Names: LY 150378

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Nonindustrial source
  • Class Class III antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Arrhythmias; Atrial fibrillation

Most Recent Events

  • 19 Oct 1998 A preclinical study has been added to the pharmacodynamics section
  • 28 Feb 1997 Two studies have been added to the adverse events, therapeutic trials and pharmacodynamics sections ,
  • 28 Feb 1997 Investigation in Atrial fibrillation in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top